Evidence map›Paper›PMID 42147442›Full record

ArticleMolecular therapy. Advances2026

The good, the bad, and the stable: Reference genes for preclinical biodistribution studies.

Klaus Mackeben, Sarah Müller, Kimberly Dolim, Michael B Otteneder, Francesca Ros, Julia Fakhiri

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Klaus MackebenRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Sarah MüllerRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Kimberly DolimRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Michael B OttenederRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
Francesca RosRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Julia FakhiriRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital PCR (dPCR) enables absolute, precise nucleic acid quantification without the need for standard curves. Still, technical variability across the sample life cycle remains a challenge in complex multi-organ preclinical studies. This study evaluated the necessity of internal reference genes (i.e., housekeeping genes; HKGs) for normalizing reverse transcription (RT)-dPCR data from recombinant adeno-associated virus (rAAV) studies in mice and non-human primates (NHPs). HKGs were ranked using statistical analysis and further evaluated with the BestKeeper and geNorm algorithms. In mice,

Indexed as

AAVbiodistributiondPCRgene therapy bioanalyticshousekeeping genesnormalizationRNA quantificationtransgene expression analysis

Identifiers

PMID42147442
PMCPMC13175771

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.